[The pathogenesis of type 2 diabetes--new aspects and clinical consequences]

Ther Umsch. 2002 Aug;59(8):381-5. doi: 10.1024/0040-5930.59.8.381.
[Article in German]

Abstract

Type 2 diabetes mellitus manifests itself in individuals who lose the ability to produce sufficient quantities of insulin to maintain normoglycemia in the face of insulin resistance. The ability to secrete adequate amounts of insulin depends on beta-cell function and mass. The endocrine pancreas has a remarkable capacity to adapt to conditions of increased insulin demand and only a minority of individuals fail to adapt and become diabetic with time. Secondary events that further reduce the function of beta-cells in type 2 diabetes mellitus are the so-called beta-cell gluco- and lipotoxicity: chronic stimulation of islets by high glucose and free fatty acid levels results in the reduction of insulin secretion. Part of these effects are reversible once these metabolites are normalized and the beta-cell re-exposed to a physiologic environment. The essential role of the beta-cell failure in type 2 diabetes is reminiscent to the pathophysiology of type 1 diabetes. The possible link between both diseases and the therapeutic implications are discussed.

Publication types

  • English Abstract

MeSH terms

  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Fatty Acids, Nonesterified / blood
  • Humans
  • Insulin / administration & dosage
  • Insulin / adverse effects
  • Insulin / blood
  • Insulin Resistance / physiology
  • Islets of Langerhans / drug effects
  • Islets of Langerhans / physiopathology*
  • Secretory Rate / drug effects
  • Secretory Rate / physiology

Substances

  • Blood Glucose
  • Fatty Acids, Nonesterified
  • Insulin